Abstract:Insulin secretion within 30 minutes of nutrient ingestion is reduced in people with cystic fibrosis (PwCF) and pancreatic insufficiency and declines with worsening glucose tolerance. The glucose potentiated arginine (GPA) test is validated for quantifying β-cell secretory capacity as an estimate of functional β-cell mass but requires technical expertise and is burdensome. This study sought to compare insulin secretion during mixed-meal tolerance testing (MMTT) to GPA-derived parameters in PwCF. Methods: Secondary data analysis of CF-focused prospective studies was performed in PwCF categorized as 1) pancreatic insufficient [PI-CF] or 2) pancreatic sufficient [PS-CF] and in 3) non-CF controls. MMTT: insulin secretory rates (ISR) were derived by parametric deconvolution using 2-compartment model of C-peptide kinetics, and incremental area under the curve (AUC) was calculated for 30, 60 and 180-minutes. GPA: acute insulin (AIR) and C-peptide responses (ACR) were calculated as average post-arginine insulin or C-peptide response minus pre-arginine insulin or C-peptide under fasting (AIR arg and ACR arg ), ~230 mg/dL (AIR pot and ACR pot ), and ~340 mg/dL (AIR max and ACR max ) hyperglycemic clamp conditions. Relationships of MMTT to GPA parameters were derived using Pearson's correlation coefficient. Predicted values were generated for MMTT ISR and compared to GPA parameters using Bland Altman analysis to assess degree of concordance. Results: 85 PwCF (45 female; 75 PI-CF and 10 PS-CF) median (range) age 23 (6-56) years with BMI 23 (13-34) kg/m 2 , HbA 1c 5.5 (3.8-10.2)%, and FEV1%-predicted 88 (26-125) and 4 non-CF controls of similar age and BMI were included. ISR AUC 30min positively correlated with AIR arg ( r =0.55), AIR pot ( r =0.62), and AIR max ( r =0.46) and with ACR arg ( r =0.59), ACR pot ( r =0.60), and ACR max ( r =0.51) (all P <0.001). ISR AUC 30min strongly predicted AIR arg (concordance=0.86), AIR pot (concordance=0.89), and AIR max (concordance=0.76) at lower mean GPA values, but underestimated AIR arg , AIR pot , and AIR max at higher GPA-defined β-cell secretory capacity. Between test agreement was unaltered by adjustment for study group, OGTT glucose category, and BMI. Conclusion: Early-phase insulin secretion during MMTT can accurately predict GPA-derived measures of β-cell function and secretory capacity when functional β-cell mass is reduced. These data can inform future multicenter studies requiring reliable, standardized, and technically feasible testing mechanisms to quantify β-cell function and secretory capacity.

Usefulness of Random Fecal α 1 ‐Antitrypsin and Chymotrypsin Determinations in Children

Fecal Short-Chain Fatty Acids as Potential Biomarkers for Attention-Deficit/Hyperactivity Disorder

Increased Intestinal Clearance of $aP 1 ‐Antitrypsin in Patients with $aP 1 ‐Antitrypsin Deficiency

Abnormal pancreatic electrolyte secretion in cystic fibrosis. Reliability as a diagnostic marker

Gut Microbiota in Children with Juvenile Idiopathic Arthritis: Characteristics, Biomarker Identification, and Usefulness in Clinical Prediction.

Low Fecal Elastase: Potentially Related to Transient Small Bowel Damage Resulting from Enteric Pathogens

Fecal proteolytic profiling of pediatric inflammatory bowel disease: A pilot study

Efficacy of Pancreatic Enzyme Supplementation in Children with Cystic Fibrosis

Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality.

Non-Invasive Markers of Inflammation and Protein Loss Augment Diagnosis of Pediatric Celiac Disease

Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels

Biochemical assessment in a cohort of pediatric patients with cystic fibrosis

The Use of Fecal Calprotectin Testing in Paediatric Disorders: A Position Paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee

Relationship of common laboratory parameters to the activity of Crohn's disease in children

Serum a-1 antitrypsin as a novel biomarker in chronic heart failure

Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients

Changes in urinary glutathione sulfonamide (GSA) levels between admission and discharge of patients with cystic fibrosis

Early-phase insulin secretion during mixed-meal tolerance testing predicts β-cell function and secretory capacity in cystic fibrosis

21: ASSESSMENT OF SERUM LEVEL OF ANTI-PSEUDOMONAS AERUGINOSA IMMUNOGLOBULIN IGG IN CHILDREN WITH CYSTIC FIBROSIS ADMITTED TO MOFID CHILDREN'S HOSPITAL IN 2013–2014

Use of Biomarkers of Inflammation in the Differentiation of Iron Deficiency and Anaemia—Lessons from Inflammatory Bowel Disease

Fecal calprotectin in pediatric gastrointestinal diseases: Pros and cons